Intelligence · Clinical Development
Pipeline search results
Programs matching “fulvestrant” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 15 pipeline programs matching "fulvestrant" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ABEMACICLIB , FULVESTRANT
Eli Lilly Co.
Breast cancer
1 trial -
Fulvestrant
Novartis Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Fulvestrant
Novartis Pharmaceuticals
Breast Cancer
1 trial -
Fulvestrant combined with Pyrotinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
1 trial -
Futibatinib, FULVESTRANT
Taiho Pharma Netherlands B.V.
Malignant Solid Tumors
1 trial -
FCN-437c+Fulvestrant
The First People's Hospital of Lianyungang
Breast Neoplasms
1 trial -
FULVESTRANT for advanced breast cancer
The George Institute
advanced breast cancer
1 trial -
FULVESTRANT, LETROZOLE
Pfizer Australia Pty Ltd
HR-positive HER2-negative metastatic/advanced BC
1 trial -
Fulvestrant
United Therapeutics Europe Ltd
Advanced Breast Cancer
1 trial -
Fulvestrant
Syndax Pharmaceuticals
Breast Cancer
1 trial -
Fulvestrant
ATOSSA THERAPEUTICS, INC.
Female Breast Carcinoma
1 trial -
Fulvestrant with Enzalutamide
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
LETROZOLE, FULVESTRANT
Pfizer Australia Pty Ltd
Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer
1 trial -
chidamide，fulvestrant
The First People's Hospital of Lianyungang
Hormone Receptor-positive Advanced Breast Cancer
1 trial -
surufatinib + fulvestrant + chidamide
The First People's Hospital of Lianyungang
Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.